Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies. / Heftdal, Line Dam; Hansen, Cecilie Bo; Hamm, Sebastian Rask; Pérez-Alós, Laura; Fogh, Kamille; Pries-Heje, Mia; Hasselbalch, Rasmus Bo; Møller, Dina Leth; Gang, Anne Ortved; Ostrowski, Sisse Rye; Frikke-Schmidt, Ruth; Sørensen, Erik; Hilsted, Linda; Bundgaard, Henning; Garred, Peter; Iversen, Kasper; Sabin, Caroline; Nielsen, Susanne Dam; Grønbæk, Kirsten.
In: Viruses, Vol. 16, No. 1, 11, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
AU - Heftdal, Line Dam
AU - Hansen, Cecilie Bo
AU - Hamm, Sebastian Rask
AU - Pérez-Alós, Laura
AU - Fogh, Kamille
AU - Pries-Heje, Mia
AU - Hasselbalch, Rasmus Bo
AU - Møller, Dina Leth
AU - Gang, Anne Ortved
AU - Ostrowski, Sisse Rye
AU - Frikke-Schmidt, Ruth
AU - Sørensen, Erik
AU - Hilsted, Linda
AU - Bundgaard, Henning
AU - Garred, Peter
AU - Iversen, Kasper
AU - Sabin, Caroline
AU - Nielsen, Susanne Dam
AU - Grønbæk, Kirsten
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2024
Y1 - 2024
N2 - To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233 patients with lymphoid malignancies (chronic lymphocytic B-cell leukemia: 73 (31.3%), lymphoma: 89 (38.2%), multiple myeloma/amyloidosis: 71 (30.5%)), who received an Omicron-adapted mRNA-based COVID-19 vaccine. IgG and neutralizing antibodies specific for the receptor-binding domain (RBD) of SARS-CoV-2 were measured using ELISA-based methods. Differences in antibody concentrations and neutralizing capacity and associations with risk factors were assessed using mixed-effects models. Over the period of vaccination with an Omicron-adapted COVID-19 vaccine, the predicted mean concentration of anti-RBD IgG increased by 0.09 log10 AU/mL/month (95% CI: 0.07; 0.11) in patients with lymphoid malignancies across diagnoses. The predicted mean neutralizing capacity increased by 0.9 percent points/month (95% CI: 0.2; 1.6). We found no associations between the increase in antibody concentration or neutralizing capacity and the variant included in the adapted vaccine. In conclusion, a discrete increase in antibody concentrations and neutralizing capacity was found over the course of Omicron-adapted vaccination in patients with lymphoid malignancies regardless of the adapted vaccine variant, indicating a beneficial effect of Omicron-adapted booster vaccination in this population.
AB - To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233 patients with lymphoid malignancies (chronic lymphocytic B-cell leukemia: 73 (31.3%), lymphoma: 89 (38.2%), multiple myeloma/amyloidosis: 71 (30.5%)), who received an Omicron-adapted mRNA-based COVID-19 vaccine. IgG and neutralizing antibodies specific for the receptor-binding domain (RBD) of SARS-CoV-2 were measured using ELISA-based methods. Differences in antibody concentrations and neutralizing capacity and associations with risk factors were assessed using mixed-effects models. Over the period of vaccination with an Omicron-adapted COVID-19 vaccine, the predicted mean concentration of anti-RBD IgG increased by 0.09 log10 AU/mL/month (95% CI: 0.07; 0.11) in patients with lymphoid malignancies across diagnoses. The predicted mean neutralizing capacity increased by 0.9 percent points/month (95% CI: 0.2; 1.6). We found no associations between the increase in antibody concentration or neutralizing capacity and the variant included in the adapted vaccine. In conclusion, a discrete increase in antibody concentrations and neutralizing capacity was found over the course of Omicron-adapted vaccination in patients with lymphoid malignancies regardless of the adapted vaccine variant, indicating a beneficial effect of Omicron-adapted booster vaccination in this population.
KW - booster
KW - COVID-19
KW - lymphoid malignancies
KW - SARS-CoV-2
KW - vaccine
KW - variant
U2 - 10.3390/v16010011
DO - 10.3390/v16010011
M3 - Journal article
C2 - 38275946
AN - SCOPUS:85183394609
VL - 16
JO - Viruses
JF - Viruses
SN - 1999-4915
IS - 1
M1 - 11
ER -
ID: 381885881